AUSTIN, Texas, April 30, 2012 /PRNewswire/ -- Luminex Corporation (LMNX) today announced financial results for the first quarter ended March 31, 2012. Financial and operating highlights include the following:
Consolidated first quarter revenue was $48.7 million, a 13 percent increase over the first quarter of 2011 First quarter assay revenue was $17.3 million, a 80 percent increase over the first quarter of 2011 First quarter shipments of 206 multiplexing analyzers that included 55 MAGPIX® systems, resulting in cumulative life-to-date multiplexing analyzer shipments of 8,884, up 12 percent from a year ago Consolidated gross profit margin was 69 percent for the first quarter of 2012 Operating expenses for the first quarter of 2012 were $28.2 million, an increase of $5.7 million over the first quarter of 2011. $2.1 million of this increase can be attributed to Luminex Madison, formerly known as EraGen Biosciences, that was acquired on June 27, 2011 Operating income for the first quarter of 2012 was $5.6 million compared with operating income of $8.3 million for the same period last year Extended a global sales and distribution agreement with Bio-Rad Laboratories, Inc. (BIO) under which Luminex has granted Bio-Rad global sales and distribution rights for Luminex's MAGPIX multiplexing analyzer and extended the strategic partnership agreement until 2023 Received CE marking for the newborn screening assay, xMAP® NeoPlex4™, and a fully automated instrument, the NeoPlex System, in April
News 
Market Data 
Discover 
